Efficacy of chemoradiotherapy combined with toripalimab in treatment of stage Ⅲ non-small cell lung cancer
Objective To investigate the efficacy of chemoradiotherapy combined with toripalimab in the treatment of stage Ⅲ non-small cell lung cancer(NSCLC).Method A total of 87 patients with stage Ⅲ NSCLC were divided into conventional chemoradiotherapy group(43 cases)and combined with toripalimab group(44 cases)according to different treatment methods.The levels of squamous cancinoma-associated antigen(SCC-Ag),thymidine kinase 1(TK1),carcino-embryonic antigen(CEA),vascular endothelial growth factor(VEGF),carbohydrate antigen 125(CA125)and T lympho-cyte subgroups were detected before and after treatment,and the occurrence of adverse reactions was recorded.Result After treatment,the levels of SCC-Ag,TK1,CEA,VEGF and CA125 were decreased,while the levels of CD3+,CD4+ and CD8+ were increased in the two groups,the levels of SCC-Ag,TK1,CEA,VEGF,CA125 and CD8+ in combined with toripalimab group were lower than those in conventional chemoradiotherapy group,while the levels of CD3+ and CD4+ were higher than those in conventional chemoradiotherapy group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in combined with toripalimab group was lower than that in conventional chemoradiotherapy group,and the difference was statistically significant(P<0.05).Conclusion Chemoradiotherapy combined with toripalimab in the treatment of stage III NSCLC patients can reduce the tumor markers level,improve im-munity,and have less adverse reactions.
万方数据
维普
